Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Affiliations
Affiliations
- Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy francesco.giorgino@uniba.it.
- 2Institute for Cellular Medicine-Diabetes, Newcastle University, Newcastle-upon-Tyne, U.K.
- 3Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland Center for Vascular Prevention, Danube-University Krems, Krems, Austria Dasman Diabetes Institute, Dasman, Kuwait Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
Abstract
The overall impact of glucose lowering on vascular complications and major clinical outcomes, including mortality, in type 2 diabetes is still an open issue. While intensive glucose control has undoubted benefit for microvascular end points, the relationship between glucose-lowering approaches and reduced incidence and/or progression of macrovascular complications is less clear. This review article will discuss the effect of glucose lowering per se as well as the effects of specific glucose-lowering therapies on vascular outcomes in type 2 diabetes. The role of lifestyle changes on cardiovascular outcomes will be also addressed. Recent analyses from large cardiovascular outcome studies (ACCORD, ADVANCE, and VADT) provide new information on factors that modulate the impact of intensive glucose lowering on outcomes, helping to identify the specific clinical characteristics of the patients receiving the intervention that would show a better response. While several studies on cardiovascular outcomes with diabetes drugs are available, they do not clearly highlight a benefit from using a specific medication or will require additional evidence, as for the sodium-glucose cotransporter 2 blockers.
Similar articles
Meier M, Hummel M.Vasc Health Risk Manag. 2009;5:859-71. doi: 10.2147/vhrm.s4808. Epub 2009 Nov 2.PMID: 19898642 Free PMC article. Review.
[Glycemic control and cardiovascular benefit: What do we know today?].
Hanefeld M, Schönauer M, Forst T.Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853. Epub 2010 Feb 9.PMID: 20146161 Review. German.
What matters in ADVANCE and ADVANCE-ON.
Hamet P.Diabetes Obes Metab. 2012 Jan;14 Suppl 1:20-9. doi: 10.1111/j.1463-1326.2011.01509.x.PMID: 22118707 Review.
Terry T, Raravikar K, Chokrungvaranon N, Reaven PD.Curr Cardiol Rep. 2012 Feb;14(1):79-88. doi: 10.1007/s11886-011-0238-6.PMID: 22160862 Review.
Tandon N, Ali MK, Narayan KM.Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000.PMID: 22217193 Review.
Cited by
Nguyen VT, Phan HL, Hoang TM, Dam TPL, Ho TH, Huynh QT.Cardiovasc Endocrinol Metab. 2021 Jun 9;10(4):210-214. doi: 10.1097/XCE.0000000000000251. eCollection 2021 Dec.PMID: 34765891 Free PMC article.
Ishibashi F, Kosaka A, Tavakoli M.Front Endocrinol (Lausanne). 2021 Apr 23;12:614161. doi: 10.3389/fendo.2021.614161. eCollection 2021.PMID: 33967950 Free PMC article.
Didangelos T, Karlafti E, Kotzakioulafi E, Margariti E, Giannoulaki P, Batanis G, Tesfaye S, Kantartzis K.Nutrients. 2021 Jan 27;13(2):395. doi: 10.3390/nu13020395.PMID: 33513879 Free PMC article. Clinical Trial.
Didangelos T, Karlafti E, Kotzakioulafi E, Kontoninas Z, Margaritidis C, Giannoulaki P, Kantartzis K.Nutrients. 2020 Oct 23;12(11):3254. doi: 10.3390/nu12113254.PMID: 33114210 Free PMC article. Clinical Trial.
CD133+Exosome Treatment Improves Cardiac Function after Stroke in Type 2 Diabetic Mice.
Venkat P, Cui C, Chen Z, Chopp M, Zacharek A, Landschoot-Ward J, Culmone L, Yang XP, Xu J, Chen J.Transl Stroke Res. 2021 Feb;12(1):112-124. doi: 10.1007/s12975-020-00807-y. Epub 2020 Mar 20.PMID: 32198711 Free PMC article.